Norman C.w. Wong

Biography

Dr. Wong is Chief Scientific Officer and co-founder of Resverlogix Corp. Dr. Wong's research interest focuses on the molecular actions of hormones related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus.  These topics of interest involved studies of chromatin structure, gene regulation and transcription factors which are major components of epigenetics.  His clinical interest encompasses patients with thyroid disease including thyroid cancer or diabetes mellitus. His most recent successes have come from elucidating the potential therapeutic opportunities for cardiovascular disease by harnessing the regulation of Apolipoprotein A-I (ApoA-I) gene expression using inhibition of BET-proteins that play important roles in epigenetics. Dr. Wong keeps active in the academic community by participating in speaking engagements at national and international medical conferences. He has been the author and co-author of more than 275 articles and abstracts and has been invited to sit on more than 40 national or international panels and committees. He has also acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories. Dr. Wong is Chief Scientific Officer and co-founder of Resverlogix Corp. Dr. Wong's research interest focuses on the molecular actions of hormones related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus.  These topics of interest involved studies of chromatin structure, gene regulation and transcription factors which are major components of epigenetics.  His clinical interest encompasses patients with thyroid disease including thyroid cancer or diabetes mellitus. His most recent successes have come from elucidating the potential therapeutic opportunities for cardiovascular disease by harnessing the regulation of Apolipoprotein A-I (ApoA-I) gene expression using inhibition of BET-proteins that play important roles in epigenetics. Dr. Wong keeps active in the academic community by participating in speaking engagements at national and international medical conferences. He has been the author and co-author of more than 275 articles and abstracts and has been invited to sit on more than 40 national or international panels and committees. He has also acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.

Research Interest

Pharmaceutical Sciences